Company Description
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States.
Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors.
The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Eric Poma |
Contact Details
Address: 4475 Executive Drive, Suite 200 San Diego, California 92121 United States | |
| Phone | 858 794 9600 |
| Website | calidibio.com |
Stock Details
| Ticker Symbol | CLDI |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001855485 |
| CUSIP Number | 320703309 |
| ISIN Number | US3207034089 |
| Employer ID | 86-2967193 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric E. Poma Ph.D. | Chief Executive Officer and Director |
| Andrew C. Jackson | Chief Financial Officer |
| Wendy Pizarro Campbell Esq. | Chief Legal, Chief Corporate Dev, Chief Diversity and Corp Secretary |
| Dr. Antonio Fernandez Santidrian Ph.D., Pharm.D. | Head of Technical Operations and Chief Scientific Officer |
| Dr. Guy Travis Clifton M.D. | Chief Medical Officer, Consultant and Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 29, 2025 | 8-K | Current Report |
| Aug 27, 2025 | SCHEDULE 13G | Filing |
| Aug 22, 2025 | 8-K | Current Report |
| Aug 21, 2025 | 424B4 | Prospectus |
| Aug 20, 2025 | EFFECT | Notice of Effectiveness |
| Aug 15, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 14, 2025 | 8-K | Current Report |
| Aug 8, 2025 | 10-Q | Quarterly Report |
| Aug 8, 2025 | 8-K | Current Report |